Page last updated: 2024-09-05

erlotinib hydrochloride and Exanthem

erlotinib hydrochloride has been researched along with Exanthem in 111 studies

Research

Studies (111)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	32 (28.83)	29.6817
2010's	70 (63.06)	24.3611
2020's	9 (8.11)	2.80

Authors

Authors	Studies
Lee, JY; Lin, CF; Liu, SY; Lo, TK; Su, PL	1
Goto, K; Hosomi, Y; Kajihara, Y; Nishio, M; Okamoto, I; Seto, T; Tajima, K; Yamamoto, N	1
Li, J; Yin, R; Yu, Y; Zou, Y	1
Chang, CJ; Chen, CB; Chen, MJ; Chen, WT; Chung, WH; Fang, YF; Hsu, PC; Hui, RC; Hung, SI; Ko, HW; Ko, YS; Li, SH; Lu, CW; Lu, KL; Lu, LY; Pang, JS; Shih, FY; Tseng, LC; Wang, CL; Wang, CW; Wu, CE	1
Chen, MJ; Chen, WQ; Fan, XX; Fang, SJ; Huang, XF; Mao, JT; Song, JJ; Tu, JF; Wu, FZ; Zhao, ZW; Zheng, LY	1
Beringer, A; Fuchs, M; Garlipp, B; Hahn, L; Heinemann, V; Kukiolka, T; Kütting, F; Malfertheiner, P; Reiser, M; Waldschmidt, DT; Westphalen, CB	1
Chang, MJ; Choi, HD	1
Li, CY; Ma, SH	1
Iwamoto, T; Julian, I	1
Boeck, S; Heinemann, V; Hichert, V; Kächele, V; Paul, T; Rüdiger, S; Scholl, C; Schumann, C; Seufferlein, T; Steffens, M; Stingl, J	1
Bury, MJ; Gandara, DR; Hirsch, FR; Kelly, K; Kwong, M; Mack, P; Miao, J; Moon, J; Moore, DF; Nguyen, DD; Redman, M; West, HL; Wozniak, AJ	1
Benesova, L; Celer, A; Fiala, O; Finek, J; Hosek, P; Kucera, R; Minarik, M; Nemcova, I; Pesek, M; Racek, J; Sorejs, O; Stehlik, P; Topolcan, O	1
Camidge, DR; Chand, VK; Fan, J; Freiwald, M; Gettinger, S; Groen, HJM; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Smit, EF; Wang, B	1
Cai, X; Shin, D; Wei, F	1
Doki, K; Hizawa, N; Homma, M; Kaburagi, T; Kurosawa, A; Ohgami, M; Shiozawa, T	1
Cao, L; Jiang, W; Liao, D; Liu, N; Xiang, D; Yang, N; Yao, D; Zhang, Y; Zhou, C	1
Chen, Y; Gu, Y; Jiang, X; Liu, Y	1
Erikson, AK; Paripati, HR; Sheedy, JT; Shoudis, SN; Sio, TT; Yu, NY	1
Ayanoglu, BT; Demirdag, HG; Yalici-Armagan, B	1
Chen, X; Duan, Y; Liao, XY; Sun, J; Wang, Y; Xu, Z; Yang, Q; Zheng, L; Zhu, B; Zhu, G	1
Bastida, C; Falchook, GS; Fu, S; Hong, DS; Jiang, Y; Kurzrock, R; Morgan-Linnell, SK; Naing, A; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, R	1
Fujita, S; Hata, A; Kaji, R; Katakami, N; Nanjo, S	1
Austin, M; Bauman, JE; Chai, X; Eaton, KD; Futran, N; Hayes, DN; Kurland, BF; Liao, JJ; Martins, RG; Mendez, E; Papagikos, MA; Parvathaneni, U; Raez, LE; Schmidt, R; Sharma, AK; Wallace, SG; Wang, DX; Yunus, F	1
Juhász, E; Kim, JH; Klingelschmitt, G; Walzer, S	1
Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S	1
Giuliani, J; Marzola, M	1
Aragane, N; Harada, T; Ichinose, Y; Kawakami, S; Kishimoto, J; Morinaga, R; Nagata, S; Nakanishi, Y; Saruwatari, K; Takayama, K; Yamada, K	1
Chen, L; Huang, Y; Liu, J; Ma, Y; Wu, H; Zhao, H; Zhou, N	1
Bria, E; Cognetti, F; Gamucci, T; Gelibter, A; Mansueto, G; Milella, M; Moscetti, L; Ruggeri, EM; Sperduti, I; Vaccaro, V	1
Amberg, N; Ansari, P; Boelke, E; Buhren, BA; Fischer, JW; Gerber, PA; Harder, J; Holcmann, M; Homey, B; Kislat, A; Lichtenberger, BM; Mackenzie, C; Röck, K; Schröder, JM; Schrumpf, H; Sibilia, M; Smolle, V; Wollenberg, A	1
Brahmer, JR; Guaglianone, PP; Hidalgo, MM; Keppen, MD; Kolesar, JM; Lee, JW; Patel, JD; Schiller, JH; Siegfried, JM; Traynor, AM	1
Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM	1
de Marinis, F; Del Signore, E; Di Maio, M; Gori, B; Passaro, A	1
Aprile, G; Ciuleanu, T; Csutor, Z; Federowicz, I; Fittipaldo, A; Hsu, C; Klughammer, B; Li, CP; Lipp, R; Meng, X; Moore, M; Nowara, E; Stemmer, SM; Tham, CK; Van Cutsem, E; Van Laethem, JL; Zeaiter, A	1
Huang, J; Ji, LJ; Liu, H; Liu, Y; Ma, W; Qi, X; Xu, M; Zhu, Y	1
Carcereny, E; de Marinis, F; Drozdowskyj, A; Dubos-Arvis, C; Passaro, A; Perez-Moreno, P; Rosell, R; Vergnenegre, A; Zeaiter, A	1
Hackshaw, A; Khan, I; Lee, SM; Morris, S	1
Chen, Q; Ding, L; Hong, X; Liang, Y; Quan, Q; Wu, H; Zhou, N	1
Frechen, S; Fuhr, U; Jaehde, U; Kocher, M; Nogova, L; Scheffler, M; Suleiman, AA; Wolf, J; Zander, T	1
Fukuoka, M; Kiyohara, Y; Kudoh, S; Seki, A; Yamazaki, N	1
Anderson, H; Burkes, RL; Chu, Q; Hao, D; Ho, C; Ho, V; Lam, W; Laskin, JJ; Lee, CW; Leighl, NB; Melosky, B; Murray, N; Sun, S; Winston, R	1
Boeck, S; Heinemann, V; Hichert, V; Kächele, V; Paul, T; Reiser, B; Rüdiger, S; Scholl, C; Schumann, C; Seufferlein, T; Sörgel, F; Steffens, M; Stelzer, C; Stingl, J; von Mallek, D	1
Chavaillon, JM; Chosidow, O; Deplanque, G; Falchero, L; Fraboulet, G; Gervais, R; Robert, C; Saal, H; Souquet, PJ; Taviot, B; Vergnenegre, A	1
Cai, F; Mao, XD; Wang, HT; Xu, J; Zhang, S	1
Addeo, R; Alaia, C; Boccellino, M; Caraglia, M; Grimaldi, A; Kast, RE; Nicoletti, GF; Quagliuolo, L	1
Kowalski, DM; Krzakowski, M; Piórek, A; Szmit, S; Zaborowska-Szmit, M	1
Biernat, W; Burzykowski, T; Duchnowska, R; Dziadziuszko, R; Jassem, J; Konopa, K; Kowalczyk, A; Limon, J; Ratajska, M; Sowa, A; Suszko-Każarnowicz, M; Szczęsna, A; Szutowicz-Zielińska, E	1
Feng, Q; Fu, X; Hackshaw, A; Mao, C; Tang, J; Yang, Z; Zhang, Y	1
Enderlein, E; Gerber, PA; Homey, B	1
Jatoi, A; Nguyen, PL	1
Hanayama, K; Hirashima, T; Imamura, F; Kanazawa, S; Kinoshita, Y; Nomura, S; Sasada, S; Siomi, K; Tujimoto, M; Yamaguchi, K	1
Xing, LN; Zhang, F	1
Karapanagiotou, EM; Merikas, I; Saif, MW; Syrigos, KN; Tsimboukis, S	1
Li, T; Perez-Soler, R	1
Ayabe, E; Endo, M; Igawa, S; Kaira, K; Kaira, R; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shimoyama, R; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N	1
Anderton, J; Davies, BR; Mark Hickinson, D; Marshall, G; Rukazenkov, Y; Speake, G; Swaisland, A; Wilkinson, RW	1
Bastus, R; Bertran-Alamillo, J; Bover, I; Camps, C; Cardenal, F; Catot, S; Garcia-Campelo, R; Gonzalez-Larriba, JL; Insa, A; Isla, D; Lopez-Vivanco, G; Majem, M; Massuti, B; Mayo, C; Molina, MA; Moran, T; Moreno, MA; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Sanchez, JJ; Sánchez, JM; Taron, M	1
Bharthuar, A; Iyer, R	1
Gao, HJ; Guo, WF; Li, JJ; Li, XY; Liu, B; Liu, XQ; Qu, LL; Tang, CH; Wang, WW; Wang, WX	1
Liao, ML; Qin, SK; Sun, Y; Wu, YL; Zhou, CC	1
Hotta, K; Inoue, K; Kishino, D; Kiura, K; Okada, T; Suzuki, E; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H	1
Eckert, R; Faehling, M; Kamp, T; Kuom, S; Schumann, C; Stoiber, KM	1
De Jonge, M; Guttman-Yassky, E; Iwata, KK; Krueger, JG; Matthews, L; McCarthy, S; Mita, A; Rowinsky, EK; Verweij, J	1
Gerami, P; Guitart, J; Lacouture, ME; Nardone, B; Newman, M; Nicholson, K; Rademaker, A; Talarico, N; West, DP; Yang, XJ	1
Dakhil, SR; Flynn, PJ; Jatoi, A; Loprinzi, CL; Mattar, BI; Nikcevich, DA; Novotny, P; Sekulic, A; Sloan, JA; Thrower, A; Wentworth-Hartung, NL	1
Altomare, G; Bidoli, P; Cazzaniga, ME; Cicchiello, F; Colombo, I; Cortinovis, DL; Crippa, A; Villa, F	1
Baba, J; Ichikawa, K; Kagamu, H; Kondo, R; Koshio, J; Miyabayashi, T; Narita, I; Ota, T; Tanaka, H; Tanaka, J; Watanabe, S; Yoshizawa, H	1
Grazioso Russi, E; Numico, G; Silvestris, N	1
Azzoli, CG; Ginsberg, MS; Janjigian, YY; Kris, MG; Krug, LM; Miller, VA; Pao, W; Pereira, LK; Pietanza, MC; Riely, GJ; Rizvi, NA	1
Buhren, BA; Gerber, PA; Homey, B; Kukova, G	1
Heigener, DF; Horwood, K; Mali, P; Reck, M; van Zandwijk, N; Wu, YL	1
Chatelut, E; Civade, E; Delord, JP; Geoerger, B; Hennebelle, I; Le Deley, MC; Thomas, F; Vassal, G; White-Koning, M	1
Balagula, Y; Boone, SL; Lacouture, ME; Luu, M; Patel, J; Rademaker, AW; Sullivan, P	1
Chu, QS; de Jonge, MJ; Hamilton, M; Iwata, K; McCarthy, S; Mita, AC; Mita, MM; Papadopoulos, K; Ricart, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Verweij, J; Wacker, B; Witt, K; Wood, L	1
Bauman, J; Belinsky, S; Fekrazad, M; Jones, D; Lee, SJ; Muller, C; Ravindranathan, M; Rutledge, T; Verschraegen, C	1
Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA	1
Aranda, E; Arrivi, A; Díaz-Rubio, E; Galán, M; Irigoyen, A; Manzano, JL; Mendez, MJ; Pericay, C; Rivera, F; Safont, MJ; Sastre, J; Valladares-Ayerbes, M	1
Boeck, S; Heinemann, V; Kächele, V; Parmar, S; Paul, T; Rüdiger, S; Schumann, C; Seeringer, A; Seufferlein, T; Stingl, JC	1
Böker, B; Grohé, C; Lüders, H	1
Gao, H; Guo, W; Li, J; Liu, X; Qin, H; Qu, L; Tang, C; Wang, H; Wang, W; Wei, X	1
Houts, AC; Leon, L; Miller, PJ; Reyes, C; Satram-Hoang, S; Schwartzberg, LS; Stepanski, EJ; Walker, MS; Wojtowicz-Praga, S	1
Antoniou, C; Katsambas, A; Nikolaou, V; Stratigos, A; Strimpakos, AS; Syrigos, KN	1
Cheng, YP; Chiu, HY; Jee, SH; Tsai, TF	1
Chen, B; Hui, Z; Liang, J; Lv, J; Wang, J; Wang, L; Wang, X; Zhai, Y; Zhu, H; Zou, S	1
Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Krejci, J; Minarik, M; Pesek, M; Ricar, J	1
Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N	1
Soulières, D	1
Pérez-Soler, R	2
Agarwala, SS; Hidalgo, M; Senzer, NN; Siu, LL; Soulieres, D; Vokes, EE	1
Bonomi, P; Chachoua, A; Clark, GM; Hammond, LA; Huberman, M; Karp, D; Pérez-Soler, R; Rigas, J; Rowinsky, EK; Santabárbara, P	1
Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN	1
Faj, D; Kurbel, S	1
Peréz-Soler, R; Saltz, L	1
Benson, K; Booth, B; Chen, YF; Chidambaram, N; Cohen, M; Duan, J; Gobburu, J; Hsieh, LS; Johnson, JR; Leighton, J; Pazdur, R; Sridhara, R; Williams, GM; Zimmerman, P	1
Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S	1
Basti, S; Benson, A; Lacouture, ME; Patel, J	1
Chou, LS; Garey, J; Kim, E; Oishi, K	1
Hwang, C; Lacouture, ME; Marymont, MH; Patel, J	1
Cagnoni, PJ; Clark, G; Nagrani, T; Wacker, B; Weinberg, J; Witt, K	1
Abbruzzese, JL; Brown, T; Chadha, R; Dancey, J; Glover, K; Morris, J; Rashid, A; Thomas, MB; Wang, X	1
Fernández-Guarino, M; Garrido López, P; González-García, C; Jaén, P	1
Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C	1
Amoroso, D; Baldari, M; Bearz, A; Bettoli, V; Cammilluzzi, E; Crinò, L; De Marinis, F; Di Pietro, FA; Gridelli, C; Grossi, F; Innocenzi, D; Maione, P; Micali, G; Piantedosi, FV; Scartozzi, M	1
Dizdar, O; Gököz, O; Yalçin, B; Yalçin, S	1
Fettner, S; Ling, J; Lum, BL; Rakhit, A; Riek, M	1
Armstrong, DK; Brahmer, JR; Carducci, MA; Chen, P; Das, S; Desai, A; Fackenthal, DL; Fleming, GF; Janisch, L; Jiang, X; Karrison, T; Liu, W; Poonkuzhali, B; Ramirez, J; Ratain, MJ; Rudin, CM; Schuetz, E; Vokes, EE	1
Chang, GC; Chang, WC; Chen, CH; Chen, HC; Chen, YM; Chu, NM; Chung, CY; Ho, ML; Hsia, TC; Hsieh, RK; Huang, MS; Kao, WY; Kuo, HP; Lai, RS; Lin, MC; Lin, ZZ; Perng, RP; Su, WC; Tsao, CJ; Wang, JL; Yang, CH; Yu, CJ; Yu, CT	1
Merikas, I; Saif, MW; Syrigos, K; Tsimboukis, S	1

Reviews

21 review(s) available for erlotinib hydrochloride and Exanthem

Article	Year
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide	2023
The efficacy and safety of erlotinib compared with chemotherapy in previously treated NSCLC: A meta-analysis. Mathematical biosciences and engineering : MBE, 2019, 08-28, Volume: 16, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mutation; Neutropenia; Odds Ratio; Patient Safety; Progression-Free Survival; Protein Kinase Inhibitors	2019
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis. PloS one, 2020, Volume: 15, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Digestive System Diseases; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Eye; Eye Diseases; Female; Gastrointestinal Tract; Humans; Kidney; Kidney Diseases; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors	2020
Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. International journal of clinical oncology, 2018, Volume: 23, Issue:3 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biliary Tract Neoplasms; Cetuximab; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Incidence; Panitumumab; Prognosis; Risk Factors	2018
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials. International journal of cancer, 2015, Jul-15, Volume: 137, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Vascular Endothelial Growth Factor A	2015
Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. BMJ open, 2016, Jun-30, Volume: 6, Issue:6 Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Middle Aged; Native Hawaiian or Other Pacific Islander; Neoplasm Staging; Smoking; Survival Analysis	2016
The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity. Current medical research and opinion, 2016, Volume: 32, Issue:11 Topics: Antineoplastic Agents; Dapsone; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Interleukin-8	2016
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. International journal of cancer, 2017, 06-15, Volume: 140, Issue:12 Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic	2017
Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. The oncologist, 2008, Volume: 13, Issue:11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Counseling; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Neoplasms; Panitumumab; Quinazolines	2008
Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. Clinical lung cancer, 2009, Volume: 10, Issue:2 Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2009
Skin toxicities associated with epidermal growth factor receptor inhibitors. Targeted oncology, 2009, Volume: 4, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Head and Neck Neoplasms; Humans; Mice; Pancreatic Neoplasms; Patient Education as Topic; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Vitamin K 3	2009
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines	2010
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? Anti-cancer drugs, 2009, Volume: 20, Issue:10 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Quinazolines; Randomized Controlled Trials as Topic	2009
A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:2 Topics: Administration, Oral; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2010
Advances in EGFR-directed therapy in head and neck cancer. Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Head and Neck Neoplasms; Humans; Lung Diseases, Interstitial; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis	2011
Identifying predictive and surrogate markers of erlotinib antitumor activity other than rash. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:11 Suppl 1 Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Patient Selection; Predictive Value of Tests; Quinazolines	2003
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:11 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome	2003
Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome	2005
Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. Clinical lung cancer, 2006, Volume: 8 Suppl 1 Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2006
Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clinical lung cancer, 2006, Volume: 8 Suppl 1 Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2006
Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP : Journal of the pancreas, 2008, May-08, Volume: 9, Issue:3 Topics: Algorithms; Antineoplastic Agents; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Genes, erbB-1; Humans; Incidence; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome	2008

Trials

45 trial(s) available for erlotinib hydrochloride and Exanthem

Article	Year
Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study. Thoracic cancer, 2022, Volume: 13, Issue:15 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors	2022
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. Science & sports, 2023, Apr-04 Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide	2023
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clinical lung cancer, 2018, Volume: 19, Issue:1 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cigarette Smoking; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome	2018
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 113 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cohort Studies; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines	2017
Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non-Small Cell Lung Cancer. Therapeutic drug monitoring, 2018, Volume: 40, Issue:6 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Interactions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Japan; Lung Neoplasms; Male; Proton Pump Inhibitors; Retrospective Studies	2018
Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations. The oncologist, 2019, Volume: 24, Issue:8 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Glucocorticoids; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonia; Progression-Free Survival; Protein Kinase Inhibitors; Radiation Injuries	2019
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget, 2013, Volume: 4, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A	2013
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-10, Volume: 31, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Male; Pain; Quinazolines; Remission Induction; Treatment Outcome	2013
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:6 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Time Factors; Treatment Outcome	2013
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:8 Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3	2013
Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803). Japanese journal of clinical oncology, 2013, Volume: 43, Issue:6 Topics: Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2013
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World journal of gastroenterology, 2013, Jul-28, Volume: 19, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Patient Selection; Proportional Hazards Models; Prospective Studies; Quinazolines; Time Factors; Treatment Outcome	2013
Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome	2014
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. Journal of hematology & oncology, 2014, Jan-03, Volume: 7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult	2014
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. British journal of cancer, 2014, Nov-25, Volume: 111, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines	2014
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial. Future oncology (London, England), 2015, Volume: 11, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Incidence; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome	2015
Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. BMJ open, 2015, Jul-02, Volume: 5, Issue:7 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality-Adjusted Life Years	2015
A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients. The AAPS journal, 2015, Volume: 17, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Markov Chains; Middle Aged; Models, Theoretical; Protein Kinase Inhibitors	2015
Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients. International journal of clinical oncology, 2016, Volume: 21, Issue:2 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Exanthema; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Product Surveillance, Postmarketing; Prognosis; Protein Kinase Inhibitors; Steroids; Survival Rate; Young Adult	2016
Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Mar-10, Volume: 34, Issue:8 Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Minocycline; Prospective Studies; Protein Kinase Inhibitors	2016
Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. Journal of the American Academy of Dermatology, 2016, Volume: 74, Issue:6 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Doxycycline; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome	2016
An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number. Oncotarget, 2017, Mar-07, Volume: 8, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome	2017
[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Smoking; Survival Rate	2010
[Efficacy and safety of Erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:2 Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate	2010
Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology, 2010, Volume: 78, Issue:3-4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Smoking; Treatment Outcome	2010
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Dendrites; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin	2010
Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). The oncologist, 2010, Volume: 15, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Medication Adherence; Middle Aged; Neoplasms; Quality of Life; Quinazolines; Sunscreening Agents	2010
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome	2011
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Quinazolines	2011
Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-15, Volume: 17, Issue:14 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Squamous Cell; Child; Child, Preschool; Cytochrome P-450 CYP3A; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Young Adult	2011
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. British journal of cancer, 2011, Sep-27, Volume: 105, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution	2011
A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Conjunctivitis; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Treatment Outcome	2012
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome	2012
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Stomatitis; Treatment Outcome	2012
Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2013, Volume: 26, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagitis; Exanthema; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiotherapy, Intensity-Modulated; Survival Rate	2013
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines	2004
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Aug-15, Volume: 22, Issue:16 Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Analysis; Treatment Outcome	2004
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-01, Volume: 10, Issue:19 Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Quinazolines; Treatment Outcome	2004
Erlotinib (Tarceva) for advanced non-small cell lung cancer. The Medical letter on drugs and therapeutics, 2005, Mar-28, Volume: 47, Issue:1205 Topics: Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Exanthema; Humans; Quinazolines	2005
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-15, Volume: 11, Issue:18 Topics: Adolescent; Adult; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis; Treatment Failure; Treatment Outcome; United States; United States Food and Drug Administration	2005
Bexarotene and erlotinib for aerodigestive tract cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured	2005
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jul-01, Volume: 13, Issue:13 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2007
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer, 2007, Sep-01, Volume: 110, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Diarrhea; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2007
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. Anti-cancer drugs, 2008, Volume: 19, Issue:2 Topics: Administration, Oral; Adult; Aged; Algorithms; Area Under Curve; Creatine Kinase; Cross-Over Studies; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fasting; Food-Drug Interactions; gamma-Glutamyltransferase; Glossitis; Hematuria; Humans; Liver; Male; Middle Aged; Molecular Structure; Patient Dropouts; Protein Kinase Inhibitors; Quinazolines; Time Factors	2008
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung cancer (Amsterdam, Netherlands), 2008, Volume: 62, Issue:1 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Salvage Therapy; Sex Factors; Smoking; Taiwan	2008

Other Studies

46 other study(ies) available for erlotinib hydrochloride and Exanthem

Article	Year
Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report. Thoracic cancer, 2022, Volume: 13, Issue:3 Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Eosinophilia; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2022
5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) for acneform rash induced by erlotinib: A case report. Photodiagnosis and photodynamic therapy, 2022, Volume: 39 Topics: Acne Vulgaris; Aminolevulinic Acid; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Photochemotherapy; Photosensitizing Agents; Skin Diseases	2022
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma. Journal of the European Academy of Dermatology and Venereology : JEADV, 2023, Volume: 37, Issue:2 Topics: Adenocarcinoma of Lung; Animals; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Rats; Retrospective Studies; Tyrosine Kinase Inhibitors; Zinc	2023
Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study. BMC cancer, 2020, Feb-24, Volume: 20, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate	2020
Necrolytic migratory erythema-like eruption associated with erlotinib in a patient with lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2020, Volume: 148 Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Necrolytic Migratory Erythema; Necrosis	2020
Investigation of Biomarkers and Handling Strategy of Erlotinib-Induced Skin Rash in Rats. Biological & pharmaceutical bulletin, 2021, Volume: 44, Issue:8 Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Exanthema; Humans; Leukocyte Common Antigens; Lung Neoplasms; Male; Neutrophils; Protein Tyrosine Phosphatases; Rats, Sprague-Dawley; Skin	2021
Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. Oncotarget, 2017, May-23, Volume: 8, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Biomarkers, Tumor; Calcifediol; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Survival Analysis	2017
Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC. Anticancer research, 2017, Volume: 37, Issue:11 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Retrospective Studies; Survival Analysis; Treatment Outcome	2017
Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation. Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Sequence Deletion	2018
Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor. International immunopharmacology, 2019, Volume: 69 Topics: Allyl Compounds; Animals; Antineoplastic Agents; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasms; Protein Kinase Inhibitors; Skin; Sulfides	2019
Erlotinib-Associated Rash Exacerbated by Whole-Brain Radiation Therapy: A Patient's Case Report. Practical radiation oncology, 2019, Volume: 9, Issue:3 Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Face; Female; Humans; Lung Neoplasms; Radiodermatitis; Skin; Treatment Outcome	2019
Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study. Cutaneous and ocular toxicology, 2019, Volume: 38, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Panitumumab; Pruritus; Retrospective Studies	2019
Dose reduction or intermittent administration of erlotinib: which is better for patients suffering from intolerable toxicities? Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:5 Topics: Aged; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2013
Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor? Archives of dermatological research, 2013, Volume: 305, Issue:7 Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies	2013
[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients]. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2013, Volume: 16, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Insurance, Health; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Outcome Assessment; Protein Kinase Inhibitors; Quinazolines	2013
Epidermal EGFR controls cutaneous host defense and prevents inflammation. Science translational medicine, 2013, Aug-21, Volume: 5, Issue:199 Topics: Animals; Antineoplastic Agents; Chemokines; Cytokines; Dermatitis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Hair Follicle; Humans; Inflammation Mediators; Interleukin-1; Keratinocytes; Langerhans Cells; Lymphocytes; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Neoplasms; Quinazolines; Skin; Translational Research, Biomedical	2013
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. Clinical lung cancer, 2014, Volume: 15, Issue:4 Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment	2014
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors. Oncotarget, 2015, Sep-22, Volume: 6, Issue:28 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors	2015
Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. European journal of cancer (Oxford, England : 1990), 2016, Volume: 55 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biotransformation; Carcinoma, Non-Small-Cell Lung; Dealkylation; Disease Progression; Disease-Free Survival; Drug Dosage Calculations; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Germany; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Severity of Illness Index	2016
A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors. Pharmacological reports : PR, 2016, Volume: 68, Issue:6 Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fibrin Fibrinogen Degradation Products; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2016
The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jun-01, Volume: 26, Issue:16 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines	2008
Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer. Platelets, 2009, Volume: 20, Issue:1 Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Quinazolines; Thromboxane B2; Treatment Outcome	2009
[Erlotnib in the treatment of advanced non-small cell lung cancer failed to previous chemotherapy]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction; Treatment Failure; Young Adult	2008
Screening for epidermal growth factor receptor mutations in lung cancer. The New England journal of medicine, 2009, Sep-03, Volume: 361, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sex Distribution; Survival Analysis; Young Adult	2009
Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 70, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Exanthema; Female; Humans; Japan; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Quinazolines; Risk	2010
Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Sep-01, Volume: 16, Issue:17 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrophy; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Immunohistochemistry; Keratin-16; Lapatinib; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin; Young Adult	2010
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:10 Topics: Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Clindamycin; Dermatologic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Isotretinoin; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome	2010
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC cancer, 2011, Jan-01, Volume: 11 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome	2011
Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology (Basel, Switzerland), 2011, Volume: 222, Issue:2 Topics: Adult; Aged; Animals; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mite Infestations; Mites; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Rosacea; Skin	2011
Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. Clinical and experimental dermatology, 2011, Volume: 36, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Incidence; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Skin Pigmentation; United States	2011
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:8 Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mometasone Furoate; Neoplasms; Pregnadienediols; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Quinazolines; Radiodermatitis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sunscreening Agents; Surveys and Questionnaires; Terminology as Topic; Tetracycline	2012
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. The pharmacogenomics journal, 2013, Volume: 13, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Association Studies; Haplotypes; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines	2013
[Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib]. Pneumologie (Stuttgart, Germany), 2012, Volume: 66, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Body Height; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Statistics as Topic; Survival Analysis	2012
The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas, 2013, Volume: 42, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Community Health Services; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Tennessee; Time Factors; Treatment Outcome	2013
Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitor-related papulopustular eruption: an effective and convenient alternative to tetracyclines. Dermatology (Basel, Switzerland), 2012, Volume: 224, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azithromycin; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Pulse Therapy, Drug; Quinazolines; Retrospective Studies; Time Factors	2012
Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field. Clinical and experimental dermatology, 2012, Volume: 37, Issue:8 Topics: Adenocarcinoma; Combined Modality Therapy; Drug Eruptions; Eczema; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines	2012
Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. Neoplasma, 2013, Volume: 60, Issue:1 Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Practice Patterns, Physicians'; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate	2013
Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer. BMC cancer, 2012, Dec-04, Volume: 12 Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Quinazolines; Real-Time Polymerase Chain Reaction	2012
Association of skin rash and tumor response to HER1/EGFR inhibition: does HER1 stimulated tumor growth depend on circulatory instead of paracrine ligands? Medical hypotheses, 2005, Volume: 64, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autocrine Communication; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Ligands; Models, Biological; Neoplasm Proteins; Neoplasms; Paracrine Communication; Quinazolines; Skin; Transforming Growth Factor alpha; Treatment Outcome	2005
The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. The journal of supportive oncology, 2006, Volume: 4, Issue:5 Topics: Algorithms; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dermatology; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Eye Diseases; Female; Humans; Interprofessional Relations; Lung Neoplasms; Medical Oncology; Middle Aged; Ophthalmology; Quinazolines; Referral and Consultation; Skin Diseases; Tacrolimus	2006
Temporal dependence of the effect of radiation on erlotinib-induced skin rash. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-20, Volume: 25, Issue:15 Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines	2007
[Erlotinib (Tarceva) induced severe exanthema]. Revista clinica espanola, 2007, Volume: 207, Issue:8 Topics: Biopsy; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin; Time Factors	2007
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anti-cancer drugs, 2007, Volume: 18, Issue:9 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography	2007
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Critical reviews in oncology/hematology, 2008, Volume: 66, Issue:2 Topics: Antineoplastic Agents; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome	2008
Sparing of previously irradiated skin from erlotinib-induced acneiform rash. Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:1 Topics: Acne Vulgaris; Adult; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Skin	2008
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7 Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Squamous Cell; Ovarian Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Quinazolines	2008